A 2025 trial of Enlicitide reported additional lipid improvements: non-high-density lipoprotein (non-HDL) cholesterol decreased by 52%, apolipoprotein B decreased by 48%, and lipoprotein(a) decreased by nearly 25% in the treatment group.
November 21, 2025
high
temporal
Secondary lipid endpoint changes observed in the same 52-week Enlicitide clinical trial.